Polymer Nanoparticles Enhance Irreversible Electroporation In Vitro

Author(s):  
Ross Aaron Petrella ◽  
Shani Leah Levit ◽  
Christopher C. Fesmire ◽  
Christina Tang ◽  
Michael B. Sano
2013 ◽  
Vol 12 (4) ◽  
pp. 304-310 ◽  
Author(s):  
Gulsim K. Kulsharova ◽  
Matthew B. Lee ◽  
Felice Cheng ◽  
Munima Haque ◽  
Hyungsoo Choi ◽  
...  

Small ◽  
2017 ◽  
Vol 13 (38) ◽  
pp. 1701582 ◽  
Author(s):  
Bohdan Andreiuk ◽  
Andreas Reisch ◽  
Marion Lindecker ◽  
Gautier Follain ◽  
Nadine Peyriéras ◽  
...  

2012 ◽  
Vol 103 (9) ◽  
pp. 2033-2042 ◽  
Author(s):  
Christopher B. Arena ◽  
Christopher S. Szot ◽  
Paulo A. Garcia ◽  
Marissa Nichole Rylander ◽  
Rafael V. Davalos

2013 ◽  
Vol 10 (3) ◽  
pp. 1092-1099 ◽  
Author(s):  
Sandani Samarajeewa ◽  
Ritu Shrestha ◽  
Mahmoud Elsabahy ◽  
Amolkumar Karwa ◽  
Ang Li ◽  
...  

Nanomaterials ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 3089
Author(s):  
Junda Zhang ◽  
Vadde Ramu ◽  
Xue-Quan Zhou ◽  
Carolina Frias ◽  
Daniel Ruiz-Molina ◽  
...  

Green light photoactive Ru-based coordination polymer nanoparticles (CPNs), with chemical formula [[Ru(biqbpy)]1.5(bis)](PF6)3 (biqbpy = 6,6′-bis[N-(isoquinolyl)-1-amino]-2,2′-bipyridine; bis = bis(imidazol-1-yl)-hexane), were obtained through polymerization of the trans-[Ru(biqbpy)(dmso)Cl]Cl complex (Complex 1) and bis bridging ligands. The as-synthesized CPNs (50 ± 12 nm diameter) showed high colloidal and chemical stability in physiological solutions. The axial bis(imidazole) ligands coordinated to the ruthenium center were photosubstituted by water upon light irradiation in aqueous medium to generate the aqueous substituted and active ruthenium complexes. The UV-Vis spectral variations observed for the suspension upon irradiation corroborated the photoactivation of the CPNs, while High Performance Liquid Chromatography (HPLC) of irradiated particles in physiological media allowed for the first time precisely quantifying the amount of photoreleased complex from the polymeric material. In vitro studies with A431 and A549 cancer cell lines revealed an 11-fold increased uptake for the nanoparticles compared to the monomeric complex [Ru(biqbpy)(N-methylimidazole)2](PF6)2 (Complex 2). After irradiation (520 nm, 39.3 J/cm2), the CPNs yielded up to a two-fold increase in cytotoxicity compared to the same CPNs kept in the dark, indicating a selective effect by light irradiation. Meanwhile, the absence of 1O2 production from both nanostructured and monomeric prodrugs concluded that light-induced cell death is not caused by a photodynamic effect but rather by photoactivated chemotherapy.


Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2208 ◽  
Author(s):  
Aleksander Kiełbik ◽  
Wojciech Szlasa ◽  
Jolanta Saczko ◽  
Julita Kulbacka

The observation that an application of a pulsed electric field (PEF) resulted in an increased permeability of the cell membrane has led to the discovery of the phenomenon called electroporation (EP). Depending on the parameters of the electric current and cell features, electroporation can be either reversible or irreversible. The irreversible electroporation (IRE) found its use in urology as a non-thermal ablative method of prostate and renal cancer. As its mechanism is based on the permeabilization of cell membrane phospholipids, IRE (as well as other treatments based on EP) provides selectivity sparing extracellular proteins and matrix. Reversible EP enables the transfer of genes, drugs, and small exogenous proteins. In clinical practice, reversible EP can locally increase the uptake of cytotoxic drugs such as cisplatin and bleomycin. This approach is known as electrochemotherapy (ECT). Few in vivo and in vitro trials of ECT have been performed on urological cancers. EP provides the possibility of transmission of genes across the cell membrane. As the protocols of gene electrotransfer (GET) over the last few years have improved, EP has become a well-known technique for non-viral cell transfection. GET involves DNA transfection directly to the cancer or the host skin and muscle tissue. Among urological cancers, the GET of several plasmids encoding prostate cancer antigens has been investigated in clinical trials. This review brings into discussion the underlying mechanism of EP and an overview of the latest progress and development perspectives of EP-based treatments in urology.


2015 ◽  
Vol 2015 (0) ◽  
pp. _J0230201--_J0230201-
Author(s):  
Masahiro YOSHIDA ◽  
Shuto YOSHIMATSU ◽  
Kosaku KURATA ◽  
Takanobu FUKUNAGA ◽  
Hiroshi TAKAMATSU

Sign in / Sign up

Export Citation Format

Share Document